 A multicentre 2-stage Phase IbII trial of 5-Azacitidine combined with Everolimus for AML patients over the age of 60 or relapsed AML over the age of 18. The MTD and DLT of 5-Azacitidine 7 doses over 9 days given monthly combined with Everolimus orally for 17 days day 5-21 each month 1 cycle for a minimum of 6 cycles and for at least 2 cycles beyond achievement of CR and for a maximum of 12 cycles. Everolimus maintenance therapy alone may be continued at investigators discretion until either progressive disease or dose limiting toxicity. Groups of 3 patients will be entered at each dose level. Dose escalationstopping rules to determine the maximum tolerated dose MTD are as follows: 